猪乳铁蛋白在4种重组乳杆菌中的表达及抑菌活性比较

为了获得优化的猪乳铁蛋白乳杆菌表达系统,并比较重组猪乳铁蛋白的抑菌活性,根据乳杆菌使用密码子的偏嗜性优化合成猪乳铁蛋白成熟肽编码序列,将其克隆到乳杆菌表达载体pPG612.1的XhoⅠ/BamHⅠ位点,获得了plf乳杆菌表达载体质粒pPG612.1-plf。将获得的重组质粒分别电转化入干酪乳杆菌ATCC393、戊糖乳杆菌KLDS1.0413、植物乳杆菌KLDS1.0344和副干酪乳杆菌KLDS1.0652细胞内,获得4种表达猪乳铁蛋白的重组乳杆菌。经木糖诱导,通过Western blotting和激光共聚焦检测重组猪乳铁蛋白的表达,用ELISA方法检测和比较4种重组菌上清中表达猪乳铁蛋白的量,并用琼脂孔穴扩散抑菌法检测4种重组乳杆菌表达乳铁蛋白的抑菌活性。结果表明,乳铁蛋白在4种重组乳杆菌中均得到正确表达,其产物分子量约73 kDa,重组干酪乳杆菌、重组戊糖乳杆菌、重组植物乳杆菌和重组副干酪乳杆菌的重组猪乳铁蛋白表达量分别为9.6μg/mL、10.8μg/mL、12.5μg/mL、9.9μg/mL。重组猪乳铁蛋白对大肠杆菌、金黄色葡萄球菌、鼠伤寒沙门氏菌、巴氏杆菌和李氏杆菌均有一定的抑菌作用,对金黄色葡萄球菌的抑菌作用最强,且4种重组乳杆菌中重组植物乳杆菌表达产物的抑菌效果优于其他重组菌的表达产物。结果表明在4种乳杆菌中重组猪乳铁蛋白的最佳表达系统为植物乳杆菌,该结果为猪乳铁蛋白的乳杆菌表达系统进一步开发与应用奠定了基础。     

基于抗菌导向的乳铁蛋白异源表达研究进展

乳铁蛋白是哺乳动物天然免疫系统和获得性免疫系统中的重要防御成分,具广泛生物学功能,包括调节体内铁平衡、广谱抗菌、抗炎症、抑制肿瘤生长、增强机体免疫力等,在医药、食品、饲料领域有重要应用价值。目前乳铁蛋白规模化生产技术瓶颈是提取成本高,利用基因重组技术构建高效表达系统是突破这一瓶颈的重要途径。基于抗菌导向的乳铁蛋白及其衍生分子在大肠杆菌、酵母、昆虫、哺乳动物和植物中表达的研究进展进行了综述。     

重组猪乳铁蛋白N端的高效表达及抑菌活性检测

为获得表达猪乳铁蛋白基因的重组菌株,并检测其表达的重组猪乳铁蛋白抑菌活性,应用RT-PCR方法从泌乳3d后母猪乳腺组织中扩增了猪乳铁蛋白N端1077bp的PLF-N基因片段,与GenBank上发表的4株猪乳铁蛋白基因序列相比,核苷酸同源性均达到99%以上。为了得到高表达量的PLF-N基因,以扩增的PLF-N片段为参考模板,经过密码子优化,全基因合成了编码猪乳铁蛋白N端的基因PLF-NS。将其定向插入到原核表达载体pET-30b中,转化大肠杆菌BL21,获得了表达PLF-NS的重组菌pET-PLF-NS/BL21;经IPTG诱导,并对表达条件进行优化,以及通过SDS-PAGE和Western blotting分析均表明猪乳铁蛋白得到了正确表达,其产物分子量约为42kDa,最优表达条件下蛋白表达量占菌体总蛋白的32%,表达产物以包涵体形式存在。包涵体经裂解、纯化、复性处理后纯度达到98%。用琼脂孔穴扩散抑菌法检测表明重组猪乳铁蛋白具有明显的抑菌作用。表明通过基因优化对表达量低的基因进行改造使之高效表达,是一种提高表达效率的有效手段。     

大鲵铁蛋白重链FTH基因的克隆、鉴定及表达分析简

从大鲵皮肤cDNA文库中,筛选出大鲵铁蛋白重链AdFTH的cDNA序列,其全长为864 bp,开放阅读框为531 bp,编码176个氨基酸,5′和3′非翻译编码区(Untranslated region,UTR)分别为120 bp和214 bp,预测蛋白质的分子量为20.6 kD,理论等电点PI为5.41,预测蛋白无信号肽及跨膜结构,在5′-UTR的22—51 bp处有一个特殊的铁反应元件(Iron response element,IRE)。同源性和系统进化分析表明,铁蛋白重链在进化上有着较高的保守性。实时定量PCR结果表明,大鲵铁蛋白重链mRNA在各个组织中广泛表达,其中肝脏的表达量高于其他8种组织,表明肝脏是大鲵主要的参与铁储存代谢的器官。成功构建了大鲵铁蛋白重链的重组表达载体pET32a-AdFTH,利用大肠杆菌Escherichia coli BL21表达系统和Ni2+亲和层析方法,获得了纯度较高的重组大鲵铁蛋白,并证实重组大鲵铁蛋白(Recombinant AdFTH protein,rAdFTH)具有氧化和吸收铁离子的功能,为进一步制备AdFTH抗体了解其在大鲵体内的多种作用机制打下坚实的基础。     

重组枯草芽孢杆菌发酵生产乳铁蛋白N叶工艺优化北大核心CSCD

为实现乳铁蛋白N叶的大规模制备,本研究对表达乳铁蛋白N叶的工程菌枯草芽孢杆菌pMA0911-D60Y/Y92D进行了发酵工艺的优化。确定了最佳的培养条件:以葡萄糖为最佳碳源,以胰蛋白胨为最佳氮源,在pH 7.0、温度28℃、发酵25.5 h条件下诱导表达目的蛋白,目的蛋白的IOD值高达68.03%。在10L发酵罐上对重组菌株的发酵条件进行优化,获得如下的最佳发酵工艺,即采用300 r/min转速,0-7 h时,在pH 7.5、30℃条件下培养菌体;7-25 h时,在pH 7.0、28℃条件下诱导表达目的蛋白。发酵结束后,收集细胞并破碎后取上清液用HisTrapHP亲和层析及SuperdexTM200(10/300GL)亲和层析法对细胞上清液进行纯化至均一条带,获得了纯度>94%的重组乳铁蛋白N叶,1 L菌体能制备23.5 mg纯蛋白。本研究为重组牛乳铁蛋白N-叶的高效制备奠定了基础。     

大鲵铁蛋白重链FTH基因的克隆、鉴定及表达分析

从大鲵皮肤cDNA文库中,筛选出大鲵铁蛋白重链AdFTH的cDNA序列,其全长为864 bp,开放阅读框为531 bp,编码176个氨基酸,5'和3'非翻译编码区（Untranslated region,UTR）分别为120 bp和214 bp,预测蛋白质的分子量为20.6 kD,理论等电点PI为5.41,预测蛋白无信号肽及跨膜结构,在5'-UTR的2251 bp处有一个特殊的铁反应元件（Iron response element,IRE）。同源性和系统进化分析表明,铁蛋白重链在进化上有着较高的保守性。实时定量PCR结果表明,大鲵铁蛋白重链mRNA在各个组织中广泛表达,其中肝脏的表达量高于其他8种组织,表明肝脏是大鲵主要的参与铁储存代谢的器官。成功构建了大鲵铁蛋白重链的重组表达载体pET32a-AdFTH,利用大肠杆菌Escherichia coli BL21表达系统和Ni2+亲和层析方法,获得了纯度较高的重组大鲵铁蛋白,并证实重组大鲵铁蛋白（Recombinant AdFTH protein,rAdFTH）具有氧化和吸收铁离子的功能,为进一步制备AdFTH抗体了解其在大鲵体内的多种作用机制打下坚实的基础。       

封面图片介绍

正乳铁蛋白(lactoferrin,LF)是乳汁中一种重要的非血红素铁结合糖蛋白,中性粒细胞颗粒中具有杀菌活性的单体糖蛋白。广泛分布于哺乳动物乳汁和其他多种组织及其分泌液中,主要由乳腺上皮细胞表达和分泌。乳铁蛋白作为一种从乳汁中提取而得的属于先天免疫系统的食品蛋白,除了具有能够结合和运输铁离子、调节体内铁的平衡的主要功能     

斑马鱼尿酸氧化酶基因的克隆与原核表达

目的探讨斑马鱼尿酸氧化酶基因的克隆与原核表达的方法,研究重组斑马鱼尿酸氧化酶(ZUO)的理化性质与生物学功能。方法用PCR的方法克隆斑马鱼尿酸氧化酶基因,用pET28a质粒进行原核表达。结果成功克隆了斑马鱼尿酸氧化酶基因并完成了测序鉴定,该基因在大肠杆菌表达系统中得到有效表达且具有体外氧化尿酸的生物学功能。目的蛋白为胞内可溶性蛋白,占可溶蛋白总量的50%左右。最佳诱导条件为27℃16 h,粗酶最佳溶解pH为9.16,在此缓冲液溶解条件下,粗酶比活性为1.94 U/mg。获得的重组ZUO产量达64.8 U/g湿菌,高于直接从动物肝脏组织萃取的尿酸氧化酶。结论斑马鱼尿酸酶基因能在大肠杆菌表达系统中表达,其溶解pH比基因工程表达的重组猪尿酸氧化酶略低,对后续开发痛风治疗新药有利。     

细菌生产人铁蛋白的新功能及应用

铁蛋白(Ferritin)是一种广泛存在于生物体中的笼状蛋白,由24个亚基自组装形成的蛋白质外壳和铁内核两部分组成,是维持机体铁代谢平衡的重要蛋白。最新发现,人血清铁蛋白含量的变化与某些疾病相关,特别是发现利用大肠杆菌重组表达、仿生合成的磁性人铁蛋白具有双功能特性,即识别肿瘤并使其可视化。此外,铁蛋白独特的结构及理化性质使其成为理想的纳米载体,用于构筑多功能肿瘤成像和药物输送的平台。本文重点介绍人铁蛋白的新功能及其在疾病诊断和肿瘤靶向治疗中的应用前景。     

牛奶过敏原β-乳球蛋白的重组制备及磁微粒化学发光检测法的建立

运用原核系统表达牛奶β-乳球蛋白(Bos d5)蛋白,建立一种纳米磁微粒化学发光方法用于检测牛奶组分过敏原β-乳球蛋白特异性Ig E抗体的含量。通过优化合成牛奶β-乳球蛋白基因,与质粒重组导入Rosetta原核表达菌株中表达目标蛋白,纯化的重组蛋白采用生物素标记后,在化学发光平台上进行过敏原项目检测。获得纯度﹥85%的22.5 kD重组牛β-乳球蛋白,将生物素化的重组蛋白用于牛奶β-乳球蛋白纳米磁微粒检测试剂盒,检测临床110例血清样本,和Phadia进行方法学比对阳性符合率为88.9%,阴性符合率97.3%,总符合率94.5%,P<0.001,χ^2=84.238,Kappa=0.874,其与Phadia参照试剂盒同样具有良好的检测能力。原核表达系统中获得的重组牛奶过敏组分β-乳球蛋白具有较好的免疫活性,开发的免疫诊断试剂盒具备良好的性能,可用于临床辅助诊断。     

High level expression of functionally active human lactoferrin in silkworm larvae

In this paper, recombinant human lactoferrin (rhLf) was expressed very well using Bombyx mori nuclear polyhedrosis baculovirus expression system. Infection of silkworm larvae with recombinant virus, vBm-hLf, the rhLf was efficiently secreted into larvae hemolymph and the concentration of product purified was about 65 microg/ml. The isolated rhLf molecular mass was approximately 78 kDa, lower than that of the human lactoferrin (hLf) standards, which may be due to incomplete glycosylation or protein degradation. Furthermore, the rhLf was characterized and its biological activities were evaluated by in vivo bioassay using dextran sodium sulfate (DSS)-induced colitis mouse model that mimics some characteristics of colitis disease in human. We conclude that silkworm expression system can be used successfully to express functional human lactoferrin.     

Novel recombinant human lactoferrin: Differential activation of oxidative stress related gene expression

Lactoferrin, an iron-binding protein found in high concentrations in mammalian exocrine secretions, is an important component of the host defense system. It is also a major protein of the secondary granules of neutrophils from which is released upon activation. Due to its potential clinical utility, recombinant human lactoferrin (rhLF) has been produced in various eukaryotic expression systems; however, none of these are fully compatible with humans. Most of the biopharmaceuticals approved by the FDA for use in humans are produced in mammalian expression systems. The Chinese hamster ovary cells (CHO) have become the system of choice for proteins that require post-translational modifications, such as glycoproteins.     

昆虫杆状病毒表达系统的研究进展与应用

昆虫杆状病毒表达载体系统具有安全性好、重组蛋白表达量高、能同时表达多个基因、重组蛋白翻译后加工完整等特点,因而得到了广泛的应用。随着重组杆状病毒构建技术的不断发展,昆虫杆状病毒表达载体系统的操作在逐渐简化,重组杆状病毒获得的效率也在不断提高。昆虫细胞培养技术的改进和转基因昆虫细胞系的发展,进一步推动了昆虫杆状病毒表达载体系统在商品化药物、治疗性抗体、生物农药研发和基因治疗中的应用。尽管仍存在着重组蛋白降解的问题,但随着分子生物学技术的发展,对杆状病毒载体的研究与改造也会更加深入,未来昆虫杆状病毒表达载体系统的应用将更为广泛。     

Recombinant human lactoferrin: A valuable protein for pharmaceutical products and functional foods

Lactoferrin, the main iron-binding protein of milk, has biological activities that are essential for the newborn and are beneficial for adults. Given this beneficial effect, there is broad interest in exogenous sources of lactoferrin in human nutrition. Consequently, several transgenic approaches to produce lactoferrin have been achieved. However, the activity of heterologous lactoferrin cannot be assumed to identically mimic that of the homologous protein. Human lactoferrin obtained from yeast, transgenic cows, and rice has met the criteria of structural similarity, high yield, and ease of protein isolation. Human lactoferrin from Aspergillus awamori has been mainly directed to therapeutic uses with advanced phases of clinical trials currently in progress. In contrast, human lactoferrin produced in transgenic cows and rice brings the clear advantage of origins compatible with use in foods, although the approval for these applications is still in process.     

Arginine 25 and Arginine 28 of lactoferrin are critical for effective heparin neutralization in blood

The interaction of lactoferrin with endogenous heparin-like molecules modulates glycosaminoglycan-mediated biological processes. We performed site-specific mutagenesis and expressed recombinant lactoferrin and lactoferrin mutants by the baculovirus insect cell expression system. Five basic residues at the lactoferrin N terminus; Arg 5, Arg 25, Arg 28, Lys 29, and Arg 31, were individually replaced by alanines. Heparin chromatography on fast-performance liquid chromatography system showed that the NaCl concentrations corresponding to the peak of each eluted recombinant protein from the column were 665, 620, 540, 550, 630, or 650 mM for wild-type recombinant lactoferrin, Arg 5, Arg 25, Arg 28, Lys 29, or Arg 31 recombinant lactoferrin mutant, respectively. We compared the ability of each mutated lactoferrin derivative to neutralize glycosaminoglycans in the thrombin serpin inhibition assays. In comparison to wild-type recombinant lactoferrin, all the mutants showed decreased ability to neutralize glycosaminoglycan in a dose-dependent manner. The mutations of lactoferrin at Arg 25 and Arg 28 demonstrated the most striking decrease in lactoferrin's ability to neutralize various glycosaminoglycans in both enzymatic and plasma clotting-based experiments. Therefore, our results suggest that Arg 25 and Arg 28 are the critical basic residues at the lactoferrin N terminus responsible for heparin binding. The other basic residues on the N terminus, Arg 5, Lys 29, and Arg 31, also contribute to heparin binding by presenting an additional cationic motif.     

Expression,purification, and characterization of equine lactoferrin in Pichia pastoris

Lactoferrin is an 80kDa iron-binding glycoprotein. It is secreted by exocrine glands. Many functions such as iron sequestering, anti-bacterial activity, regulation of gene expression, and immunomodulation are attributed to it. In the present study, we report the production of recombinant equine lactoferrin (ELF) in the methylotropic yeast Pichia pastoris using pPIC9K vector. The recombinant protein was purified by one-step affinity chromatography using heparin-Sepharose column. The purified protein has a molecular weight of 80kDa and reacted with antibody raised against the native equine lactoferrin. Its N-terminal sequence was identical to that of the native ELF. The iron-binding behavior and circular dichroism studies of the purified protein indicate that it has folded properly. The recombinant protein appears to be hyperglycosylated by the host strain, GS115. This is the first heterologous expression of equine lactoferrin and also the first report of intact lactoferrin expression using P. pastoris system. An yield of 40mg/l obtained in shake-flask cultures with this system, which is higher than the reported values for other systems.     

Production of recombinant human lactoferrin from transgenic plants

Molecular farming provides a powerful tool for low cost production of recombinant proteins with pharmaceutical value. The use of transgenic plants has been increasingly tested as alternative system for obtaining biologically active human lactoferrin in plants. Precise selection of plant species, transformation techniques and expression cassettes, in addition to conduction of detailed glycosylation and immunogenicity studies, serves as basis of obtaining safe recombinant human lactoferrin in high concentrations for the use of pharmacy. On the other hand, expression of antimicrobial protein lactoferrin in plants is a promising opportunity for crop quality improvement by increasing plant disease resistance.     

Bovine lactoferrin and lactoferricin derived from milk: production and applications.

Bovine lactoferrin is produced on an industrial scale from cheese whey or skim milk. The safety of purified lactoferrin has been confirmed from the results of a reverse mutation test using bacteria, a 13-week oral repeated-dose toxicity study in rats, and clinical studies. In order to apply active lactoferrin to various products, a process for its pasteurization was developed. Subsequently, lactoferrin has been used in a wide variety of products since it was first added to infant formula in 1986. A pepsin hydrolysate of lactoferrin is also used in infant formula. This hydrolysate contains a potent antimicrobial peptide named lactoferricin that is derived from the lactoferrin molecule by pepsin digestion. Semilarge-scale purification of lactoferricin can be performed by hydrophobic interaction chromatography. Lactoferricin also exhibits several biological actions and appears to be the functional domain of lactoferrin. Recent studies have demonstrated that oral administration of lactoferrin or lactoferricin exerts a host-protective effect in various animals and in humans. The results of these studies strongly suggest that the effects of oral lactoferrin are mediated by modulation of the immune system. Further elucidation of the clinical efficacy and mechanism of action of lactoferrin will increase the value of lactoferrin-containing products.